Clinical Trial Update: Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 pilot trial evaluating raltegravir (Isentress) in relapsing-remitting multiple sclerosis. The study has completed and results were posted in May 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Sponsor: Queen Mary University of London | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30